1. Home
  2. PHAR vs WLDN Comparison

PHAR vs WLDN Comparison

Compare PHAR & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.31

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Willdan Group Inc.

WLDN

Willdan Group Inc.

HOLD

Current Price

$109.64

Market Cap

1.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
WLDN
Founded
1988
1964
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.6B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
PHAR
WLDN
Price
$16.31
$109.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$38.00
$114.33
AVG Volume (30 Days)
22.5K
191.7K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.17
EPS
0.00
2.79
Revenue
$362,274,000.00
$651,926,000.00
Revenue This Year
$24.80
N/A
Revenue Next Year
$6.84
$9.01
P/E Ratio
$2,946.57
$39.91
Revenue Growth
26.78
12.90
52 Week Low
$7.50
$30.43
52 Week High
$18.12
$121.00

Technical Indicators

Market Signals
Indicator
PHAR
WLDN
Relative Strength Index (RSI) 51.06 65.20
Support Level $16.23 $101.00
Resistance Level $17.00 $109.62
Average True Range (ATR) 0.75 4.33
MACD -0.16 0.39
Stochastic Oscillator 36.44 98.21

Price Performance

Historical Comparison
PHAR
WLDN

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

Share on Social Networks: